- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic hepatitis D
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 July 2025 March 2026 Meetings - (PDF)
- Public Summary Document (PSD) March 2025 July 2025 March 2026 Meetings - (DOCX)
Bulevirtide – March 2025
Bulevirtide; Powder for injection 2 mg; Hepcludex® – March 2025 – July 2025
Last updated
12 March 2025